Kuros Biosurgery AG - Product Pipeline Review - 2014

Kuros Biosurgery AG - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Kuros Biosurgery AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kuros Biosurgery AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Kuros Biosurgery AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kuros Biosurgery AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Kuros Biosurgery AG’s pipeline products

Reasons to buy

- Evaluate Kuros Biosurgery AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kuros Biosurgery AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kuros Biosurgery AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kuros Biosurgery AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kuros Biosurgery AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kuros Biosurgery AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Kuros Biosurgery AG - Product Pipeline Review - 2014

EyeGene, Inc. - Product Pipeline Review - 2014

EyeGene, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the EyeGene, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of EyeGene, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of EyeGene, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of EyeGene, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the EyeGene, Inc.’s pipeline products

Reasons to buy

- Evaluate EyeGene, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of EyeGene, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the EyeGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of EyeGene, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of EyeGene, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of EyeGene, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit EyeGene, Inc. - Product Pipeline Review - 2014

Delpor, Inc. - Product Pipeline Review - 2014

Delpor, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Delpor, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Delpor, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Delpor, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Delpor, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Delpor, Inc.’s pipeline products

Reasons to buy

- Evaluate Delpor, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Delpor, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Delpor, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Delpor, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Delpor, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Delpor, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Delpor, Inc. - Product Pipeline Review - 2014

UMN Pharma Inc. - Product Pipeline Review - 2014

UMN Pharma Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the UMN Pharma Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UMN Pharma Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of UMN Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of UMN Pharma Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the UMN Pharma Inc.’s pipeline products

Reasons to buy

- Evaluate UMN Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of UMN Pharma Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the UMN Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of UMN Pharma Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of UMN Pharma Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of UMN Pharma Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit UMN Pharma Inc. - Product Pipeline Review - 2014

Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014

Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Sinil Pharmaceutical Co., Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sinil Pharmaceutical Co., Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Sinil Pharmaceutical Co., Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sinil Pharmaceutical Co., Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sinil Pharmaceutical Co., Ltd’s pipeline products

Reasons to buy

- Evaluate Sinil Pharmaceutical Co., Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sinil Pharmaceutical Co., Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sinil Pharmaceutical Co., Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sinil Pharmaceutical Co., Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sinil Pharmaceutical Co., Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sinil Pharmaceutical Co., Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Sinil Pharmaceutical Co., Ltd - Product Pipeline Review - 2014

Ocular Therapeutix, Inc. - Product Pipeline Review - 2014

Ocular Therapeutix, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Ocular Therapeutix, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ocular Therapeutix, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Ocular Therapeutix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ocular Therapeutix, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ocular Therapeutix, Inc.’s pipeline products

Reasons to buy

- Evaluate Ocular Therapeutix, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ocular Therapeutix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ocular Therapeutix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ocular Therapeutix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ocular Therapeutix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ocular Therapeutix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Ocular Therapeutix, Inc. - Product Pipeline Review - 2014

VTT Technical Research Centre of Finland - Product Pipeline Review - 2014

VTT Technical Research Centre of Finland - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the VTT Technical Research Centre of Finland’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of VTT Technical Research Centre of Finland’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of VTT Technical Research Centre of Finland including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of VTT Technical Research Centre of Finland’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the VTT Technical Research Centre of Finland’s pipeline products

Reasons to buy

- Evaluate VTT Technical Research Centre of Finland’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of VTT Technical Research Centre of Finland in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the VTT Technical Research Centre of Finland’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of VTT Technical Research Centre of Finland and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of VTT Technical Research Centre of Finland
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of VTT Technical Research Centre of Finland and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit VTT Technical Research Centre of Finland - Product Pipeline Review - 2014

MultiCell Technologies, Inc. - Product Pipeline Review - 2014

MultiCell Technologies, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the MultiCell Technologies, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MultiCell Technologies, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of MultiCell Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MultiCell Technologies, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the MultiCell Technologies, Inc.’s pipeline products

Reasons to buy

- Evaluate MultiCell Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MultiCell Technologies, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MultiCell Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MultiCell Technologies, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MultiCell Technologies, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of MultiCell Technologies, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit MultiCell Technologies, Inc. - Product Pipeline Review - 2014

Pharming Group N.V. - Product Pipeline Review - 2014

Pharming Group N.V. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Pharming Group N.V.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharming Group N.V.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Pharming Group N.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharming Group N.V.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pharming Group N.V.’s pipeline products

Reasons to buy

- Evaluate Pharming Group N.V.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharming Group N.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharming Group N.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharming Group N.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharming Group N.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Pharming Group N.V. - Product Pipeline Review - 2014